Like Nader said yesterday, they are publishing many papers on the different aspects and uses of Leronlimab for Nash GBHD etc.
Those separate papers are pure gold in terms of the scientist and medical readership in the millions all combined. Then other lesser science journals pick up the stories that the masses then read in Forbes, WallStreet Journal, Nature magazine etc etc etc etc etc etc.